X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Natrunix is an immunoglobulin cloned from healthy human donor which blocks IL-1α it is being investigated in combination with chemotherapy regimen for pancreatic cancer.
Lead Product(s): Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: Natrunix
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Details:
Hutrukin therapy is intended to be provided immediately prior to the clot-busting procedure, where the drug may reduce inflammatory injury associated with reperfusion. is being developed to reduce brain injury following ischemic stroke.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Hutrukin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Natrunix (vilamakitug) is a unique kind of drug, an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor, and is investigated in combination with chemotherapy for treating pancreatic cancer.
Lead Product(s): Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area: Oncology Product Name: Natrunix
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Natrunix (human IgG4 monoclonal antibody) is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor and blocks inflammation in rheumatoid arthritis.
Lead Product(s): Vilamakitug
Therapeutic Area: Immunology Product Name: Natrunix
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor and blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α).
Lead Product(s): Human IgG4 Monoclonal Antibody
Therapeutic Area: Immunology Product Name: Natrunix
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Hutrukin therapy is intended to be provided immediately prior to the clot-busting procedure, where the drug may reduce inflammatory injury associated with reperfusion. is being developed to reduce brain injury following ischemic stroke.
Lead Product(s): Hutrukin
Therapeutic Area: Neurology Product Name: Hutrukin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
The Natrunix (XB2001), antibody therapy represents a groundbreaking approach to therapy—with the aim to of reducing treatment related toxicity of chemotherapy while also blocking the tumor-associated signals that spurn growth and spread of tumors.
Lead Product(s): XB2001
Therapeutic Area: Oncology Product Name: Natrunix
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer in subjects that have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine.
Lead Product(s): XB2001,Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: Natrunix
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: The French National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 28, 2022
Details:
Natrunix is a new drug, discovered and manufactured at XBiotech’s research and development headquarters in Austin, Texas. The Company believes Natrunix holds promise as a breakthrough therapy for the treatment of inflammatory joint diseases.
Lead Product(s): XB2001
Therapeutic Area: Rheumatology Product Name: Natrunix
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
XBiotech True Human antibodies are derived without modification from individuals who possess natural immunity to certain diseases. True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
Lead Product(s): CAR90972
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CAR90972
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
